- Home
- SCWO vs NRXS Comparison
SCWO vs NRXS Comparison
Compare SCWO & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | SCWO | NRXS |
|---|---|---|
| Founded | 2021 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.2M | 46.3M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | SCWO | NRXS |
|---|---|---|
| Price | $2.46 | $5.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 106.7K | 68.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,685,925.00 |
| Revenue This Year | $5,945.19 | $31.05 |
| Revenue Next Year | $106.82 | $146.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 9.18 |
| 52 Week Low | $0.16 | $1.33 |
| 52 Week High | $3.55 | $6.20 |
Technical Indicators
Market Signals| Indicator | SCWO | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 47.63 | 71.40 |
| Support Level | $2.60 | $5.21 |
| Resistance Level | $2.89 | $5.56 |
| Average True Range (ATR) | 0.26 | 0.36 |
| MACD | -0.11 | 0.08 |
| Stochastic Oscillator | 2.86 | 92.66 |
Price Performance
Historical ComparisonAbout SCWO 374Water Inc.
374Water Inc offers a technology that transforms wet wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, and forever chemicals (e.g., PFAS) into recoverable resources by focusing on waste as a valuable resource for water, energy, and minerals. The company's business activities include manufacturing processes and waste recycling and treatment processes, which currently involve the use, treatment, storage, transfer, handling and/or disposal of hazardous materials, chemicals and wastes.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).